Novo Nordisk’s Wegovy wins EU backing for reducing heart risks
Novo Nordisk’s Wegovy has received backing from the EU’s medical regulator to expand the weight loss drug’s use to reducing the rise of serious heart events.
Novo Nordisk’s Wegovy has received backing from the EU’s medical regulator to expand the weight loss drug’s use to reducing the rise of serious heart events.
